Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Jan

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Multiple Myeloma Sex Differences in Etiology and Clinical Presentation

Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive mCRPC

Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma